Blog

 

Blog

Africa Stand Up: Navigating the new world order

14 February 2017

By Amma Boakye and Andrew Skipper

Following a year of landmark political changes, could it be that the time has never been more opportune for Africa to seize control of its place in the global market? In this blog post our Africa Practice explores if Africa can act positively to avoid losing out on the agenda of global leaders and influencers and take advantage of the disrupted landscape to put its house in order and negotiate its own deals.

Read the full blog post here.

Read more

Jurisdictions: United Kingdom, U.S., Africa

Blog

The Article 50 process: What happens now?

9 February 2017

By Charles Brasted

Last night the Article 50 Bill, which allows the Prime Minister to begin withdrawal talks under Article 50, was approved by the House of Commons. In this blog, we briefly outline the expected next steps and timeline.

Read more

Jurisdictions: United Kingdom

Blog

Relocation of the EU Medicines Agency: Italy

9 February 2017

By Riccardo Fruscalzo

The EU Medicines Agency (EMA), the most sought after EU regulator, is looking for a new home. 900 jobs will move from London to an EU Member State when Brexit is complete. In a series of blog posts, our European life science and healthcare colleagues pitch their home country as the new location for the EMA. In our first post, Riccardo Fruscalzo, a Counsel based in our Milan offices, argues the case for Italy.

Read more

Industries: Life Sciences and Healthcare
Jurisdictions: Italy

Blog

Brexit – The Art of the Deal?

2 February 2017

By Peter Watts

Today's White Paper sets out a bold aspiration. The UK as a global pivot. A Strategic Partnership with the EU; a Special Relationship with the US.

Read more

Jurisdictions: United Kingdom

Blog

Brexit: Could mutuality be the key?

1 February 2017

By Helen Kimberley

With the UK Government firmly indicating a "Hard Brexit", regulatory cooperation between the UK and EU is set to be key for a number of industries post-Brexit. Jeremy Hunt, the Secretary of State for Health, has recognised that while he does not expect the UK to remain part of the EU medicines regulatory framework (read more here), he expects the UK to continue to work closely with the European Medicines Agency (EMA) and potential mutual recognition between the MHRA (The Medicines and Healthcare products Regulatory Agency in the UK) and the EMA. Arguably, and as Mr Hunt emphasised, this is something that would benefit both the UK and the EU and will be encouraging for the UK life sciences industry. 

Read more

Industries: Life Sciences and Healthcare
Jurisdictions: United Kingdom